Are you over 18 and want to see adult content?
More Annotations
A complete backup of forexnewsnow.com
Are you over 18 and want to see adult content?
A complete backup of crimeapress.info
Are you over 18 and want to see adult content?
A complete backup of premiumthemes.in
Are you over 18 and want to see adult content?
A complete backup of remax-quebec.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of michaelbigalke.de
Are you over 18 and want to see adult content?
A complete backup of amazonaws.com.cn
Are you over 18 and want to see adult content?
A complete backup of standardtime.com
Are you over 18 and want to see adult content?
Text
PHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. GSK’S PD-1 INHIBITOR JEMPERLI APPROVED IN THE UK GSK’s PD-1 inhibitor Jemperli approved in the UK. 7th June 2021. by. Lucy Parsons. GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer. Specifically, Jemperli (dostarlimab) has been granted a IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Imophoron develops COVID-19 vaccine candidates. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373 deaths. UK biotech Imophoron says it has produced multiple COVID-19 vaccine candidates based on its novel vaccine platform ADDomer. COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES COVID and the growing threat of counterfeit medicines. 29th April 2021. by. Mike Seed. Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcaresystems
PHARMA R&D: 2021 AND BEYOND Pharma R&D: 2021 and beyond. 4th February 2021. by. Naomi Ikeda. The pharmaceutical sector emerges into 2021 with exciting prospects. The race for a COVID-19 vaccine has stimulated innovation across the industry, but the sector has been building momentum for years. Prior to the current pandemic, the UK health and pharma industry was growingat
CLINICAL RESEARCHER OF THE YEAR Clinical Researcher of the Year - The Americas 2021. The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning andFINALISTS 2021
Finalists 2021 - International Clinical Researcher of the Year - Competitions - PharmaTimes 15 YEARS OF BIOSIMILAR ACCESS IN EUROPE In Europe, biosimilars have now captured 10% of the total biologics market value, most of that (7%) in the past five years. By volume, the amount is substantially higher, reflecting the steadily increasing level of savings due to growing biosimilar competition and penetration. 4. Today, more than 60 biosimilars have been approved foruse in the
ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. NOVARTIS UK ANNOUNCES FURTHER HRT PATCH STOCK ISSUES Novartis says it is expecting an additional temporary stock shortage of its HRT patch Estradot TTS-75, due to “manufacturing constraints”. Temporary stock shortages of around four weeks for Estradot TTS-75 and TTS 37.5 were first announced in January because of a printing issue, though were subsequently resolved.PHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. GSK’S PD-1 INHIBITOR JEMPERLI APPROVED IN THE UK GSK’s PD-1 inhibitor Jemperli approved in the UK. 7th June 2021. by. Lucy Parsons. GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer. Specifically, Jemperli (dostarlimab) has been granted a IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Imophoron develops COVID-19 vaccine candidates. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373 deaths. UK biotech Imophoron says it has produced multiple COVID-19 vaccine candidates based on its novel vaccine platform ADDomer. COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES COVID and the growing threat of counterfeit medicines. 29th April 2021. by. Mike Seed. Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcaresystems
PHARMA R&D: 2021 AND BEYOND Pharma R&D: 2021 and beyond. 4th February 2021. by. Naomi Ikeda. The pharmaceutical sector emerges into 2021 with exciting prospects. The race for a COVID-19 vaccine has stimulated innovation across the industry, but the sector has been building momentum for years. Prior to the current pandemic, the UK health and pharma industry was growingat
CLINICAL RESEARCHER OF THE YEAR Clinical Researcher of the Year - The Americas 2021. The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning andFINALISTS 2021
Finalists 2021 - International Clinical Researcher of the Year - Competitions - PharmaTimes 15 YEARS OF BIOSIMILAR ACCESS IN EUROPE In Europe, biosimilars have now captured 10% of the total biologics market value, most of that (7%) in the past five years. By volume, the amount is substantially higher, reflecting the steadily increasing level of savings due to growing biosimilar competition and penetration. 4. Today, more than 60 biosimilars have been approved foruse in the
ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. NOVARTIS UK ANNOUNCES FURTHER HRT PATCH STOCK ISSUES Novartis says it is expecting an additional temporary stock shortage of its HRT patch Estradot TTS-75, due to “manufacturing constraints”. Temporary stock shortages of around four weeks for Estradot TTS-75 and TTS 37.5 were first announced in January because of a printing issue, though were subsequently resolved.NEWS - PHARMATIMES
BREAKING NEWS: UK approves J&J’s one-dose COVID-19 vaccine. UK’s Vaccine Taskforce has secured 20 million doses of the vaccine, withinitial
NEW HYBRID HEALTHCARE AGENCY STIRRED LAUNCHES 4 hours ago · Stirred – a new hybrid healthcare agency – has been launched this week by former senior Pegasus colleagues Jo Spadaccino and Stuart Hehir. Between them, Spadaccino and Hehir have over 40 years’ experience in marketing and communications, having been part of the shareholding team that grew PATIENT PARTNERSHIP INDEX 2021 1 day ago · Celebrating and showcasing the top examples of partnerships between pharmaceutical companies and patient groups, the Patient Partnership Index 2021 results have been announced – with three companies awarded GOLD for their partnership work NOVARTIS ORAL THERAPY IPTACOPAN SHOWS PROMISE IN PNH 4 hours ago · Novartis has revealed new positive data for its investigational treatment iptacopan as a monotherapy treatment for patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH). The data, presented at the Annual Congress ofthe
MODUS THERAPEUTICS PARTNERS WITH IMPERIAL COLLEGE LONDON 4 hours ago · Swedish biotech company Modus Therapeutics has announced a new collaboration with Imperial College London to research the effects of its drug sevuparin in patients with severe malaria. The research collaboration will be undertaken by a team led by NICE BROADENS ACCESS TO TREATMENTS FOR RHEUMATOID 4 hours ago · The National Institute for Health and Care Excellence (NICE) has published final draft guidance broadening access to several treatment for patients with moderate to severe rheumatoid arthritis. The final appraisal document has recommended biologics, including anti-TNF blockers adalimumab and MHRA APPROVES VENCLYXTO FOR NEWLY DIAGNOSED AML 4 hours ago · The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AbbVie and Roche’s Venclyxto for the treatment of newly diagnosed acute myeloid leukaemia (AML). The MHRA has cleared Venclyxto (venetoclax) in combination with a BAYER SUBSIDIARY DOSES FIRST PATIENT WITH PARKINSON’S 1 day ago · German pharma company Bayer has announced that it has made progress in its ‘two-pronged’ approach to deliver cell and gene therapy candidates for the treatment of Parkinson’s disease. BlueRock Therapeutics, a wholly-owned subsidiary of Bayer, has administered the first dose of DA01 – stem CELL AND GENE THERAPY CATAPULT FORMS CONSORTIUM OF OVER 20 1 day ago · The Cell and Gene Therapy (CGT) Catapult has announced the formation of a consortium of over 20 organisations, which will aim to accelerate technology development in cell and gene therapy manufacturing. The consortium consists of pharmaceutical companies, technology providers, therapy developers and ASTELLAS’ XTANDI BAGS NICE APPROVAL IN PROSTATE CANCER 1 day ago · Astellas’ oral treatment Xtandi has received approval from the National Institute for Health and Care Excellence (NICE) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The positive decision is supported by data from the Phase III ARCHES trial, which showed XtandiPHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. GSK’S PD-1 INHIBITOR JEMPERLI APPROVED IN THE UK GSK’s PD-1 inhibitor Jemperli approved in the UK. 7th June 2021. by. Lucy Parsons. GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer. Specifically, Jemperli (dostarlimab) has been granted a IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Imophoron develops COVID-19 vaccine candidates. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373 deaths. UK biotech Imophoron says it has produced multiple COVID-19 vaccine candidates based on its novel vaccine platform ADDomer. COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES COVID and the growing threat of counterfeit medicines. 29th April 2021. by. Mike Seed. Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcaresystems
PHARMA R&D: 2021 AND BEYOND Pharma R&D: 2021 and beyond. 4th February 2021. by. Naomi Ikeda. The pharmaceutical sector emerges into 2021 with exciting prospects. The race for a COVID-19 vaccine has stimulated innovation across the industry, but the sector has been building momentum for years. Prior to the current pandemic, the UK health and pharma industry was growingat
CLINICAL RESEARCHER OF THE YEAR Clinical Researcher of the Year - The Americas 2021. The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning andFINALISTS 2021
Finalists 2021 - International Clinical Researcher of the Year - Competitions - PharmaTimes 15 YEARS OF BIOSIMILAR ACCESS IN EUROPE In Europe, biosimilars have now captured 10% of the total biologics market value, most of that (7%) in the past five years. By volume, the amount is substantially higher, reflecting the steadily increasing level of savings due to growing biosimilar competition and penetration. 4. Today, more than 60 biosimilars have been approved foruse in the
ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. NOVARTIS UK ANNOUNCES FURTHER HRT PATCH STOCK ISSUES Novartis says it is expecting an additional temporary stock shortage of its HRT patch Estradot TTS-75, due to “manufacturing constraints”. Temporary stock shortages of around four weeks for Estradot TTS-75 and TTS 37.5 were first announced in January because of a printing issue, though were subsequently resolved.PHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. GSK’S PD-1 INHIBITOR JEMPERLI APPROVED IN THE UK GSK’s PD-1 inhibitor Jemperli approved in the UK. 7th June 2021. by. Lucy Parsons. GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer. Specifically, Jemperli (dostarlimab) has been granted a IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Imophoron develops COVID-19 vaccine candidates. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373 deaths. UK biotech Imophoron says it has produced multiple COVID-19 vaccine candidates based on its novel vaccine platform ADDomer. COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES COVID and the growing threat of counterfeit medicines. 29th April 2021. by. Mike Seed. Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcaresystems
PHARMA R&D: 2021 AND BEYOND Pharma R&D: 2021 and beyond. 4th February 2021. by. Naomi Ikeda. The pharmaceutical sector emerges into 2021 with exciting prospects. The race for a COVID-19 vaccine has stimulated innovation across the industry, but the sector has been building momentum for years. Prior to the current pandemic, the UK health and pharma industry was growingat
CLINICAL RESEARCHER OF THE YEAR Clinical Researcher of the Year - The Americas 2021. The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning andFINALISTS 2021
Finalists 2021 - International Clinical Researcher of the Year - Competitions - PharmaTimes 15 YEARS OF BIOSIMILAR ACCESS IN EUROPE In Europe, biosimilars have now captured 10% of the total biologics market value, most of that (7%) in the past five years. By volume, the amount is substantially higher, reflecting the steadily increasing level of savings due to growing biosimilar competition and penetration. 4. Today, more than 60 biosimilars have been approved foruse in the
ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. NOVARTIS UK ANNOUNCES FURTHER HRT PATCH STOCK ISSUES Novartis says it is expecting an additional temporary stock shortage of its HRT patch Estradot TTS-75, due to “manufacturing constraints”. Temporary stock shortages of around four weeks for Estradot TTS-75 and TTS 37.5 were first announced in January because of a printing issue, though were subsequently resolved.NEWS - PHARMATIMES
BREAKING NEWS: UK approves J&J’s one-dose COVID-19 vaccine. UK’s Vaccine Taskforce has secured 20 million doses of the vaccine, withinitial
PATIENT PARTNERSHIP INDEX 2021 21 hours ago · Celebrating and showcasing the top examples of partnerships between pharmaceutical companies and patient groups, the Patient Partnership Index 2021 results have been announced – with three companies awarded GOLD for their partnership work CELL AND GENE THERAPY CATAPULT FORMS CONSORTIUM OF OVER 20 1 day ago · The Cell and Gene Therapy (CGT) Catapult has announced the formation of a consortium of over 20 organisations, which will aim to accelerate technology development in cell and gene therapy manufacturing. The consortium consists of pharmaceutical companies, technology providers, therapy developers and ENTRY CLOSING NEXT FRIDAY FOR CROY 2021 Entry for the 2021 Clinical Researcher of the Year – The Americas will be closing next Friday the 18 th of June.. The 2021 competition is already shaping up to be another hotly contested event, and there is still time for clinical researchers from across the BAYER SUBSIDIARY DOSES FIRST PATIENT WITH PARKINSON’S 1 day ago · German pharma company Bayer has announced that it has made progress in its ‘two-pronged’ approach to deliver cell and gene therapy candidates for the treatment of Parkinson’s disease. BlueRock Therapeutics, a wholly-owned subsidiary of Bayer, has administered the first dose of DA01 – stem TICKETS NOW ON SALE FOR INTCR 2021 Individual tickets or tables are now available for the 2021 International Clinical Researcher of the Year awards. Despite the turbulent year, the competition has once again seen great entry numbers across all of the hotly contested categories – the finalists now all eagerly await their chance to go for gold at the virtualfinals day.
AMICUS' POMPE DISEASE THERAPY JOINS EARLY ACCESS SCHEME 1 day ago · Patients with late-stage Pompe disease who are failing to respond to enzyme replacement therapy will now have early access to an alternative treatment option, after Amicus Therapeutics' cipaglucosidase alfa with miglustat was approved for the UK's Early Access to Medicine Scheme (EAMS). ASTELLAS’ XTANDI BAGS NICE APPROVAL IN PROSTATE CANCER 1 day ago · Astellas’ oral treatment Xtandi has received approval from the National Institute for Health and Care Excellence (NICE) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The positive decision is supported by data from the Phase III ARCHES trial, which showed XtandiCONNECTING THE DOTS
The pharmaceutical industry, with the clinical trial process at its core, operates on a truly global scale, conducting studies to determine the safety and efficacy of therapies and vaccines, fundamental to the advancement of human health. For those involved in the facilitation of clinical trials OPDIVO COMBOS SHOW OS BENEFIT IN ADVANCED OESOPHAGEAL 1 day ago · Bristol Myers Squibb’s (BMS) immunotherapy Opdivo, when administered alongside chemotherapy or Yervoy, demonstrated significant overall survival (OS) benefit compared to chemotherapy alone in advanced/metastatic oesophageal cancer patients. Interim analysis data from the Phase III CheckMate-648PHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Imophoron develops COVID-19 vaccine candidates. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373 deaths. UK biotech Imophoron says it has produced multiple COVID-19 vaccine candidates based on its novel vaccine platform ADDomer. COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES COVID and the growing threat of counterfeit medicines. 29th April 2021. by. Mike Seed. Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcaresystems
COMMUNICATIONS AWARDS Communications Awards. The PharmaTimes Communications Awards are back for 2021, giving the opportunity for communications professionals to demonstrate their leadership, creative, and teamwork skills in a variety of fun and engaging virtual challenges. CLINICAL RESEARCHER OF THE YEAR Clinical Researcher of the Year - The Americas 2021. The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning and INTERNATIONAL CLINICAL RESEARCHER OF THE YEAR International Clinical Researcher of the Year 2021. Raising standards in clinical research for over 20 years. After an innovative 2020 competition which saw our finalists compete virtually, the 2021 competition has launched, offering once again a renowned challenge designed to test, develop, and reward clinical researchers working allover the globe.
ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. OPDIVO PLUS YERVOY MOVES CLOSER TO EU APPROVAL FOR DMMR Bristol Myers Squibb’s (BMS) Opdivo plus Yervoy combination therapy has moved closer to EU approval for certain colorectal cancer patients, after scoring a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The CHMP has recommended EMA ACCEPTS ASTELLAS/SEAGEN’S ENFORTUMAB VEDOTIN FOR The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for Astellas and Seagen’s enfortumab vedotin. Astellas/Seagen’s MAA is seeking authorisation of enfortumab vedotin for the treatment of adult patients with locally advanced or metastatic urothelial (bladder) cancer, who have received a PD-1 or PD-L1 inhibitor and a platinum-based chemotherapy in PATIENT HEALTH BUDGETS: A POSITIVE OR NEGATIVE DEVELOPMENT 17th April 2018. by. Rohit Patni. This week the NHS announced that it was going to be giving a greater number of patients their own budgets to source healthcare services. Building on the 23,000 people across the UK who already collect personal finances through the NHS’s Continuing Healthcare initiative, it’s reported that now as many asPHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Imophoron develops COVID-19 vaccine candidates. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373 deaths. UK biotech Imophoron says it has produced multiple COVID-19 vaccine candidates based on its novel vaccine platform ADDomer. COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES COVID and the growing threat of counterfeit medicines. 29th April 2021. by. Mike Seed. Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcaresystems
COMMUNICATIONS AWARDS Communications Awards. The PharmaTimes Communications Awards are back for 2021, giving the opportunity for communications professionals to demonstrate their leadership, creative, and teamwork skills in a variety of fun and engaging virtual challenges. CLINICAL RESEARCHER OF THE YEAR Clinical Researcher of the Year - The Americas 2021. The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning and INTERNATIONAL CLINICAL RESEARCHER OF THE YEAR International Clinical Researcher of the Year 2021. Raising standards in clinical research for over 20 years. After an innovative 2020 competition which saw our finalists compete virtually, the 2021 competition has launched, offering once again a renowned challenge designed to test, develop, and reward clinical researchers working allover the globe.
ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. OPDIVO PLUS YERVOY MOVES CLOSER TO EU APPROVAL FOR DMMR Bristol Myers Squibb’s (BMS) Opdivo plus Yervoy combination therapy has moved closer to EU approval for certain colorectal cancer patients, after scoring a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The CHMP has recommended EMA ACCEPTS ASTELLAS/SEAGEN’S ENFORTUMAB VEDOTIN FOR The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for Astellas and Seagen’s enfortumab vedotin. Astellas/Seagen’s MAA is seeking authorisation of enfortumab vedotin for the treatment of adult patients with locally advanced or metastatic urothelial (bladder) cancer, who have received a PD-1 or PD-L1 inhibitor and a platinum-based chemotherapy in PATIENT HEALTH BUDGETS: A POSITIVE OR NEGATIVE DEVELOPMENT 17th April 2018. by. Rohit Patni. This week the NHS announced that it was going to be giving a greater number of patients their own budgets to source healthcare services. Building on the 23,000 people across the UK who already collect personal finances through the NHS’s Continuing Healthcare initiative, it’s reported that now as many as TICKETS NOW ON SALE FOR INTCR 2021 1 day ago · Individual tickets or tables are now available for the 2021 International Clinical Researcher of the Year awards. Despite the turbulent year, the competition has once again seen great entry numbers across all of the hotly contested categories – the finalists now all eagerly await their chance to go for gold at the virtualfinals day.
ENTRY CLOSING NEXT FRIDAY FOR CROY 2021 12 hours ago · Entry for the 2021 Clinical Researcher of the Year – The Americas will be closing next Friday the 18 th of June.. The 2021 competition is already shaping up to be another hotly contested event, and there is still time for clinical researchers from acrossthe
AMGEN’S KRAS INHIBITOR LUMAKRAS SCORES POSITIVE OVERALL 1 day ago · Amgen has presented new data on overall survival (OS) for its KRAS inhibitor Lumakras in previously treated non-small cell lung cancer (NSCLC) at the 2021 American Society of Clinical Oncology (ASCO) annual meeting. The Phase II results of the CodeBreaK SMC BACKS FIVE NEW MEDICINES FOR NHS USE 11 hours ago · Servier's Lonsurf and AstraZeneca's Calquence are among the positive decisions - News - PharmaTimes NEW RESEARCH IDENTIFIES SINGLE BIOMARKER THAT CAN INDICATE 11 hours ago · New research has identified a single biomarker that can be used to accurately identify underlying neurodegeneration among people with cognitive issues. The new study, led by King’s College London, examined samples from 3138 samples, including people BIOGEN, EISAI’S ALZHEIMER’S DRUG ADUCANUMAB MAKES HISTORY 11 hours ago · The US Food and Drug Administration (FDA) has granted Biogen and Eisai’s aducanumab and accelerated approval, making it the first new treatment approved for Alzheimer's disease in over a decade. The accelerated approval for aducanumab – now known asAduhelm –
MHRA AUTHORISES PFIZER/BIONTECH’S COVID-19 VACCINE FOR 12 1 day ago · The UK Medicines and Healthcare products Regulatory Agency (MHRA) has extended the authorisation of Pfizer/BioNTech’s COVID-19 vaccine for use in children aged 12 to 15 years old. On Friday, the MHRA announced that it had concluded that the NICE RECOMMENDS TECENTRIQ FOR FIRST-LINE NSCLC 11 hours ago · The UK National Institute for Health and Care Excellence (NICE) has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer (NSCLC). Tecentriq (atezolizumab) is indicated for adults with metastatic NSCLC if their tumours have PD-L1 expression on GSK’S PD-1 INHIBITOR JEMPERLI APPROVED IN THE UK 1 day ago · GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer. Specifically, Jemperli (dostarlimab) has been granted a conditional marketing authorisation for IKSUDA THERAPEUTICS RAISES $47M TO PROGRESS ADC PIPELINE 1 day ago · Newcastle, UK-headquartered Iksuda Therapeutics has announced the closing of a $47m (£34m) financing round, with the funds to be used to support the advancement of its lead antibody drug conjugate (ADC) assets. This includes the company’s leadPHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Imophoron develops COVID-19 vaccine candidates. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373 deaths. UK biotech Imophoron says it has produced multiple COVID-19 vaccine candidates based on its novel vaccine platform ADDomer. COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES COVID and the growing threat of counterfeit medicines. 29th April 2021. by. Mike Seed. Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcaresystems
CLINICAL RESEARCHER OF THE YEAR Clinical Researcher of the Year - The Americas 2021. The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning and INTERNATIONAL CLINICAL RESEARCHER OF THE YEAR International Clinical Researcher of the Year 2021. Raising standards in clinical research for over 20 years. After an innovative 2020 competition which saw our finalists compete virtually, the 2021 competition has launched, offering once again a renowned challenge designed to test, develop, and reward clinical researchers working allover the globe.
REAL-WORLD DATA SUGGESTS SPUTNIK V VACCINE IS 97.6% Lucy Parsons. New real-world data has suggested that Russia’s Sputnik V vaccine is 97.6% effective against COVID-19, the Gamaleya Institute and the Russian Direct Investment Fund (RDIF) announced yesterday. The new efficacy rate is based on the analysis of data from 3.8 million Russians vaccinated with both components of Sputnik V from ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. AZ BAGS POSITIVE RESULTS IN INVESTIGATIONAL LUPUS DRUG AZ bags positive results in investigational Lupus drug trial. 29th August 2019. by. Anna Smith. AstraZeneca has announced that its potential new systemic lupus erythematosus (SLE) medicine, anifrolumab, has met its primary endpoint, achieving a statistically-significant and clinically-meaningful reduction indisease activity.
PFIZER LAUNCHES CHRONIC PAIN CAMPAIGN 29th January 2013. by. Selina McKee. Drug giant Pfizer has this morning launched a new campaign designed to get patients suffering from chronic pain talking to each other, to improve communication and accelerate diagnosis of the condition. The Pain Exchange is an online forum designed to promote conversation about pain between patients tohelp
FAILURE TO LAUNCH
A new report delves into why so many pharma brands struggle to launch and what can be done about it There has never been a more challenging time for product launch in the pharmaceutical industry, conclude the authors of a new report from management consultants Eden McCallum.“Approvals are
PHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Imophoron develops COVID-19 vaccine candidates. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373 deaths. UK biotech Imophoron says it has produced multiple COVID-19 vaccine candidates based on its novel vaccine platform ADDomer. COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES COVID and the growing threat of counterfeit medicines. 29th April 2021. by. Mike Seed. Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcaresystems
CLINICAL RESEARCHER OF THE YEAR Clinical Researcher of the Year - The Americas 2021. The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning and INTERNATIONAL CLINICAL RESEARCHER OF THE YEAR International Clinical Researcher of the Year 2021. Raising standards in clinical research for over 20 years. After an innovative 2020 competition which saw our finalists compete virtually, the 2021 competition has launched, offering once again a renowned challenge designed to test, develop, and reward clinical researchers working allover the globe.
REAL-WORLD DATA SUGGESTS SPUTNIK V VACCINE IS 97.6% Lucy Parsons. New real-world data has suggested that Russia’s Sputnik V vaccine is 97.6% effective against COVID-19, the Gamaleya Institute and the Russian Direct Investment Fund (RDIF) announced yesterday. The new efficacy rate is based on the analysis of data from 3.8 million Russians vaccinated with both components of Sputnik V from ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. AZ BAGS POSITIVE RESULTS IN INVESTIGATIONAL LUPUS DRUG AZ bags positive results in investigational Lupus drug trial. 29th August 2019. by. Anna Smith. AstraZeneca has announced that its potential new systemic lupus erythematosus (SLE) medicine, anifrolumab, has met its primary endpoint, achieving a statistically-significant and clinically-meaningful reduction indisease activity.
PFIZER LAUNCHES CHRONIC PAIN CAMPAIGN 29th January 2013. by. Selina McKee. Drug giant Pfizer has this morning launched a new campaign designed to get patients suffering from chronic pain talking to each other, to improve communication and accelerate diagnosis of the condition. The Pain Exchange is an online forum designed to promote conversation about pain between patients tohelp
FAILURE TO LAUNCH
A new report delves into why so many pharma brands struggle to launch and what can be done about it There has never been a more challenging time for product launch in the pharmaceutical industry, conclude the authors of a new report from management consultants Eden McCallum.“Approvals are
TICKETS NOW ON SALE FOR INTCR 2021 1 day ago · Individual tickets or tables are now available for the 2021 International Clinical Researcher of the Year awards. Despite the turbulent year, the competition has once again seen great entry numbers across all of the hotly contested categories – the finalists now all eagerly await their chance to go for gold at the virtualfinals day.
ENTRY CLOSING NEXT FRIDAY FOR CROY 2021 10 hours ago · Entry for the 2021 Clinical Researcher of the Year – The Americas will be closing next Friday the 18 th of June.. The 2021 competition is already shaping up to be another hotly contested event, and there is still time for clinical researchers from acrossthe
AMGEN’S KRAS INHIBITOR LUMAKRAS SCORES POSITIVE OVERALL 1 day ago · Amgen has presented new data on overall survival (OS) for its KRAS inhibitor Lumakras in previously treated non-small cell lung cancer (NSCLC) at the 2021 American Society of Clinical Oncology (ASCO) annual meeting. The Phase II results of the CodeBreaK SMC BACKS FIVE NEW MEDICINES FOR NHS USE 9 hours ago · Most read articles Janssen’s myeloma CAR T therapy cilta-cel demonstrates ‘sustained efficacy’ Novartis reports 'clinically relevant' survival data for Lutathera MHRA AUTHORISES PFIZER/BIONTECH’S COVID-19 VACCINE FOR 12 1 day ago · The UK Medicines and Healthcare products Regulatory Agency (MHRA) has extended the authorisation of Pfizer/BioNTech’s COVID-19 vaccine for use in children aged 12 to 15 years old. On Friday, the MHRA announced that it had concluded that the NEW RESEARCH IDENTIFIES SINGLE BIOMARKER THAT CAN INDICATE 9 hours ago · New research has identified a single biomarker that can be used to accurately identify underlying neurodegeneration among people with cognitive issues. The new study, led by King’s College London, examined samples from 3138 samples, including people GSK’S PD-1 INHIBITOR JEMPERLI APPROVED IN THE UK 1 day ago · GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer. Specifically, Jemperli (dostarlimab) has been granted a conditional marketing authorisation for IKSUDA THERAPEUTICS RAISES $47M TO PROGRESS ADC PIPELINE 1 day ago · Newcastle, UK-headquartered Iksuda Therapeutics has announced the closing of a $47m (£34m) financing round, with the funds to be used to support the advancement of its lead antibody drug conjugate (ADC) assets. This includes the company’s lead BIOGEN, EISAI’S ALZHEIMER’S DRUG ADUCANUMAB MAKES HISTORY 9 hours ago · The US Food and Drug Administration (FDA) has granted Biogen and Eisai’s aducanumab and accelerated approval, making it the first new treatment approved for Alzheimer's disease in over a decade. The accelerated approval for aducanumab – now known asAduhelm –
NICE RECOMMENDS TECENTRIQ FOR FIRST-LINE NSCLC 9 hours ago · The UK National Institute for Health and Care Excellence (NICE) has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer (NSCLC). Tecentriq (atezolizumab) is indicated for adults withmetastatic
Our website uses cookies to improve your experience. You can change your cookie settings at any time, otherwise we'll assume you're OK tocontinue Learn more
Remove this message
* Subscribe
* Advertise
* About us
__ __
__
__
Go
* Magazine
* Web Exclusives
* News
* Competitions
* Appointments
* Jobs
* Business Insights
* Webinars
* Thought Leadership__
__
*
* Magazine
* Overview
* Latest Issue
* Business Insights
* Subscribe
* Have your Say
* Media information
* Magazine Archive
* Web Exclusives
*
* News
* News
* Free news subscriptions* Free RSS Feed
*
* Competitions
* Overview
*
* Marketer
* Marketer of the year* Overview
* Where & When
* Enter
* Nominate
* Latest News
* How the Competition Works* Categories
* Testimonials
* Gallery
* Alumni
* Sponsors
* Steering Group
* Sponsorship Opportunities* Become a Judge
* Contact Us
*
* Communications Team * Communications Team of the year* Overview
* Where & When
* Enter
* Nominate
* Categories
* Latest News
* How the Competition Works* Testimonials
* Gallery
* Alumni
* Sponsors
* Steering Group
* Sponsorship Opportunities* Become a Judge
* Contact Us
*
* International Clinical Researcher * International Clinical Researcher of the Year* Overview
* 2020 Winners
* Finalists 2020
* Where & When
* Categories
* How It Works
* Enter
* Nominate
* Executive Steering Group* Alumni
* Gallery
* Videos
* Testimonials
* Sponsorship Opportunities* Sponsors
* Latest News
* Terms & Conditions* Privacy Policy
* Contact Us
*
* Clinical Researcher - The Americas * Clinical Researcher of the Year - The Americas* Overview
* How the competition works* Categories
* Enter
* Nominate
* Executive Steering Group* Alumni
* Winners 2020
* Gallery
* Videos
* Testimonials
* Sponsorship Opportunities* Sponsors
* Latest News
* Terms & Conditions* Privacy Policy
* Contact Us
*
* Sales Awards
* Sales Awards
* Overview
* Where & When
* Enter
* Nominate
* Latest News
* How the Competition Works* Categories
* Testimonials
* Gallery
* Alumni
* Sponsors
* Steering Group
* Sponsorship Opportunities* Become a Judge
* Contact Us
*
* Medical & Scientific Excellence Awards * Medical & Scientific Excellence Awards* Overview
* 2019 Results
* Book Tickets
* Where & When
* Enter
* Nominate
* Latest News
* How the Competition Works* Categories
* Testimonials
* Alumni
* Gallery
* Sponsors
* Steering Group
* Sponsorship Opportunities* Become a Judge
* Contact Us
* Appointments
* Jobs
* Business Insights
* Thought Leadership* Subscribe
* Advertise
* About us
COVID-19: KEEP UP TO DATE WITH THE LATEST PHARMACEUTICAL AND HEALTHCARE NEWS AS THE PANDEMIC EVOLVES*
STAR TRACKING ACROSS THE PHARMAVERSE While the COVID-19 menace has wreaked havoc across global industries, pharma’s commitment to logistical zeal has provided a supersonic slipstream to optimal performance, not to mention salvation for millions of patients*
DATA – THE KEY TO RESHAPING PATIENT PATHWAYS Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset*
ARTIFICIAL INVENTORS The question of artificial intelligence as an inventor – and what it means for drug discoveryNEWS
View all
AMAZON LAUNCHES ONLINE PHARMACY IN THE US Service also offers price comparison on generic and branded drugs20th November 2020
SOSEI HEPTARES’ COVID-19 PROGRAMME ADVANCES PROMISING MOLECULES R&D programme is focused on developing small molecules againstSARS-CoV-2 virus
20th November 2020
ALNYLAM'S RNAI THERAPEUTIC OXLUMO GETS EU GREEN LIGHT Treatment approved to treat primary hyperoxaluria type 120th November 2020
NOVARTIS SECURES RIGHTS TO MESOBLAST’S REMESTEMCEL-L FOR ARDS Drug is currently being evaluated in a phase III COVID-19-related ARDSstudy
20th November 2020
NOVEL ANTIBIOTIC RECARBRIO HAS LAUNCHED IN THE UK Combination treatment scored EU approval earlier this year19th November 2020
TOP TRENDING
*
GILEAD AND NOVO NORDISK’S NASH TRIAL MEETS PRIMARY ENDPOINT*
PFIZER TO BUILD R&D FACILITY IN WUHAN, CHINA*
AMAZON LAUNCHES ONLINE PHARMACY IN THE US*
NHS LAUNCHES 40 ‘LONG COVID’ CLINICS*
VIIV’S CABOTEGRAVIR SCORES BREAKTHROUGH DESIGNATION FOR HIVPREVENTION
*
AZ’S COVID-19 VACCINE PRODUCES ‘ENCOURAGING’ IMMUNE RESPONSE INOLDER ADULTS
WEB EXCLUSIVES
View all
A PRIME TARGET
How can pharma protect itself from cyber criminals? PHARMACOVIGILANCE IN A PANDEMIC WORLD Infusing automation into pharmacovigilance for COVID-19 treatments CREATIVE MED AFFAIRS AND BRIDGING THE HEALTHCARE GAP Med affairs will need to take an increasingly significant role when it comes to engaging with patients and HCPs to unlock the full potential of healthcare, and creativity is the key EMBRACING DIGITALISATION Five golden rules for pharma businesses to power sales from digital and e-commerce platformsMAGAZINE
View more from the latest edition PATIENT FILES: SPINAL MUSCULAR ATROPHY (SMA) Cheryl Yoder shares her family’s experiences with this rare, geneticdisorder
BRANCHING OUT
Pharma companies have improved how they engage with healthcare providers during COVID-19, says Accenture’s Brad Michel DECENTRALISING RESEARCH Revolutionising clinical trials with wearables and digital endpoints REINVENTING PATIENT ENGAGEMENT Lessons from the Patient Partnership Index conference ARTIFICIAL INVENTORS The question of artificial intelligence as an inventor – and what it means for drug discovery KEEPING TRIAL DATA ALIVE Insight into the conduct of clinical trials and managing data amid thepandemic
MAINTAINING CROSS-BORDER MEDICINES SUPPLY Updated guidelines from the European Medicines Agency for pharmaceuticals marketing authorisation holders offer new clarity on what they must do to maintain continuity of supply of UK-registered products in Europe once the Brexit transition period ends. RETHINKING CANCER DETECTION If we are to truly beat cancer, we need to pay as much attention to detecting it as we do treating itTHOUGHT LEADERSHIP
View all
THE CONCORDANCE CONUNDRUM – THE TECH DIVIDE Consultations in a virtual world THE CONCORDANCE CONUNDRUM: THE VALUE OF IMPROVING PATIENT EXPERIENCE The art of active listening NEW PRODUCT VS ESTABLISHED BRAND INVESTMENT? A trade-off you no longer have to make in this changing world CHANGING GEAR – HOW TO TAKE PATIENT-CENTRICITY TO THE NEXT LEVEL Truly achieving a patient-focused cultural shift means pharma leaders must build momentum behind the necessity of partnering with patients to capture and incorporate their valuable insights, say Dawn Lobbanand Peter Impey
WEBINARS
View all
DESIGNING PHARMA ORGANISATIONS FOR SUCCESS Across all industries, people are changing the ways they engage with products, services, and brands. View more... _Wednesday, 28 September 2016 - 11:00 am_George Underwood
FREE - Listen again now - | VIEW NOW Get the latest pharma news delivered to your inbox A valid email address is required.Subscribe for free
LATEST JOBS
View all
PUMP EDUCATOR - DIABETESNegotiable
MSL LEAD
Negotiable
REGIONAL ACCOUNT MANAGER - RESPIRATORY - SOUTH EAST ENGLAND Competitive Salary and Bonus TRAINING MANAGER - ONCOLOGY - WEST LONDON Competitive Salary and Bonus MEDICAL SCIENCE LIAISON - AESTHETICS - UK NORTH Competitive Salary and Bonus BRAND MANAGER - NEUROLOGY - HERTFORDSHIRE Competitive Salary and Bonus What job are you looking for? This field is required.Find jobs
SOCIAL MEDIA
LATEST VIDEOS
Marketer, Communications Team of the year and Sales awardsLATEST ON INSTAGRAM
Visit PharmaTimes Media Ltd's profile on Instagram.LATEST TWEETS
DOWNLOAD OUR APPS
Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app. Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.CONTENT
* News
* Magazine
* Advertise
* Contact
* Competitions
CONNECT
* __ RSS
* __ Instagram
* __ Vine
* __ Pinterest
* __ Twitter
* __ Linkedin
LEGAL
* Privacy policy
* Terms and Conditions* Editorial policy
* Cookies
* RSS - feed subscriptions Copyright PharmaTimes Media Limited 2020Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0